
About Domain Therapeutics
Domain Therapeutics is a Healthcare company based in Strasbourg (France) founded in 2008. GPCR-targeted drug candidates for immuno-oncology and inflammation are developed. Domain Therapeutics has raised $51.19 million across 6 funding rounds from investors including Banque Populaire, Caisse D Epargne and CIC. Domain Therapeutics has completed 2 acquisitions, including NEUROFIT and Prestwick Chemical. Its chief executive, as recorded, is Sean A MacDonald. Domain Therapeutics offers products and services including DT-9081, DT-7012, and DT-9046. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Developer of GPCRtargeted immunooncology and inflammation drug candidates. It offers small molecule and antibody therapeutics targeting G proteincoupled receptors involved in immune suppression and tumor microenvironment modulation. Its proprietary platform supports the identification and validation of novel GPCR targets. Key programs focus on oral EP4 receptor antagonists for solid tumors, Tregdepleting antiCCR8 antibodies, and PAR2 negative allosteric modulators for inflammatory diseases. The pipeline emphasizes precision therapy guided by biomarker strategies, aiming to enhance immune response and address resistance mechanisms in cancer and inflammation.
- Headquarters Strasbourg, France
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website domaintherapeutics.com
- Social LinkedIn X Facebook Instagram
- Annual Revenue$7.71 M (USD)-31as on Dec 31, 2023
- Net Profit-$14.24 M (USD)-65as on Dec 31, 2023
- EBITDA-$17.64 M (USD)-55as on Dec 31, 2023
- Total Equity Funding$51.19M (USD)
in 6 rounds
- Latest Funding Round$42M (USD), Series A
May 2022
- InvestorsBanque Populaire
& 23 more
- Investments & AcquisitionsNEUROFIT
& 1 more
Products & Services of Domain Therapeutics
Domain Therapeutics offers a comprehensive portfolio of products and services, including DT-9081, DT-7012, and DT-9046.
EP4 receptor antagonist for treating solid tumors.
Anti-CCR8 antibody for solid tumor depletion.
Biased PAR2 antagonist for inflammation management.
Funding Insights of Domain Therapeutics
Domain Therapeutics has successfully raised a total of $51.19M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $42 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.19M
- Total Rounds 6
- Last Round Series A β $42M
- First Round $2.82M
(Dec 2008)
- Investors Count 24
All 6 funding rounds of Domain Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | $42M | Series A | β | Panacea Venture, CTI Life Sciences Fund | |
| Jan 2020 | $6.67M | Debt – Conventional | β | β | |
| May 2019 | $3.92M | Series A | β | Seventure Partners | β |
| Apr 2014 | $230,000 | Grant | β | β | |
| Jul 2012 | $2.45M | Series A | β | Seventure Partners | |
| Dec 2008 | $2.82M | Seed | β | β |
24 investors in total: 22 institutional and 2 angel.
Investors in Domain Therapeutics
Domain Therapeutics has secured backing from 24 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Banque Populaire, Caisse D Epargne and CIC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A life sciences venture fund is operated with global reach. | panaceaventure.com | |||
Venture capital investments are made in life sciences companies. | ctisciences.com | Montreal, Canada | ||
Early-stage healthcare investments are made by 3B Future Health Fund. | 3bfuturehealth.com | Luxembourg, Luxembourg | ||
Private equity investments are made in companies across diverse sectors. | turennecapital.com | Paris, France | ||
Private equity firm focused on energy transition and sustainable investments across Europe. | omnescapital.com | |||
Theodorus is engaged in managing investment funds for research innovation. | theodorus.be | Brussels, Belgium | ||
Biotechnology startups are incubated and funded by Viva BioInnovator. | 2014 | vivabioinnovator.com | Shanghai, China | |
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US | seventure.fr | Paris, France | ||
SODIV is engaged in supporting SMEs in Grand Est. | sodiv.fr | Mulhouse, France | ||
Venture capital investments are managed by Auriga Partners in France. | 1998 | aurigapartners.com | Paris, France |
Investor details for Domain Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Domain Therapeutics
29 people are tracked at Domain Therapeutics (10 in leadership, 11 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Sean A MacDonald | CEO | Leadership |
Clément Jodeau | Head of Legal | Leadership |
Marjorie Sidhoum | Director, Business Development | Leadership |
Asmaa Boudribila | Medical Director | Leadership |
Thibaut Brugat | Head Of Portfolio | Leadership |
Stanislas-Léonard Malmezat | CFO | Leadership |
Nathalie Lenne | VP, Strategic Portfolio Management | Leadership |
Stephan Schann | VP, Research | Leadership |
Orphée Blanchard | Head of Innovation and Immunology group | Leadership |
Stanislas MALMEZAT | Chief Financial Officer - CFO - Biotech / Drug discovery / Clinical development | Leadership |
Antoine Italiano | Scientific Advisor | Board & advisors |
John Stagg | Scientific Advisory Board Member | Board & advisors |
James Huang | Director | Board & advisors |
J. Silvio Gutkind | Scientific Advisor | Board & advisors |
Aurélie Maisner | Directeur Des Ressources Humaines | Board & advisors |
Michel Bouvier | Chairman, Scientific Advisory Board | Board & advisors |
Guy Le Houillier | Director | Board & advisors |
Emmanuel Fiessinger | Director | Board & advisors |
Laurence Rulleau | Director | Board & advisors |
Roberto De Ponti | Director | Board & advisors |
9 more people are available in the full profile.
Complete people profiles for Domain Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Domain Therapeutics
Domain Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include NEUROFIT and Prestwick Chemical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provides chemical screening libraries and customized medicinal chemistry services to drug developers | prestwickchemical.com | Illkirch Graffenstaden, France | 1999 | Dec 2019 | β’β’β’β’ | |
A preclinical CRO specializing in nervous system disorder treatments. | neurofit.com | Illkirch Graffenstaden, France | 1996 | Dec 2019 | β’β’β’β’ |
Complete acquisition details for Domain Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Domain Therapeutics
5 dated milestones of Domain Therapeutics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Domain Therapeutics is founded.
- Funding First funding round of $2.8M.
- Acquisition Acquires NEUROFIT.
- Acquisition Acquires Prestwick Chemical.
- Funding Latest funding round, Series A, of $42.0M.
Web traffic of Domain Therapeutics
The website of Domain Therapeutics (domaintherapeutics.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 36% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Domain Therapeutics
Complete news archive for Domain Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Domain Therapeutics
Domain Therapeutics was founded in 2008.
Domain Therapeutics is headquartered in Strasbourg, France. It is registered at Strasbourg, Grand Est, France.
Sean A MacDonald is the CEO of Domain Therapeutics, as recorded in our data.
Domain Therapeutics is a funded company, having raised a total of $51.19M across 6 funding rounds to date. The company's 1st funding round was a Seed of $2.82M, raised on Dec 2008.
Annual revenue of Domain Therapeutics is $7.71M as on Dec 31, 2023.
Developer of GPCRtargeted immunooncology and inflammation drug candidates. It offers small molecule and antibody therapeutics targeting G proteincoupled receptors involved in immune suppression and tumor microenvironment modulation. Its proprietary platform supports the identification and validation of novel GPCR targets. Key programs focus on oral EP4 receptor antagonists for solid tumors, Tregdepleting antiCCR8 antibodies, and PAR2 negative allosteric modulators for inflammatory diseases. The pipeline emphasizes precision therapy guided by biomarker strategies, aiming to enhance immune response and address resistance mechanisms in cancer and inflammation.
Domain Therapeutics offers DT-9081, DT-7012, and DT-9046.
Domain Therapeutics has made 2 acquisitions, including NEUROFIT, and Prestwick Chemical.
Domain Therapeutics has 24 investors. Key investors include Banque Populaire, Caisse D Epargne, CIC, AGF Management Limited, and Bpifrance.
